Targeting virulence: A new paradigm for antimicrobial therapy

Nature Chemical Biology

Volumn 3, Issue 9, 2007, Pages 541-548

  Clatworthy, Anne E ^a   Pierson, Emily ^a   Hung, Deborah T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 FLUORO 3 METHYLPHENYL)SULFONYLAMINO] N HYDROXY 2 (TETRAHYDRO 2H PYRAN 4 YL)ACETAMIDE; ANTIINFECTIVE AGENT; ARGININE; BACTERIAL TOXIN; CIPROFLOXACIN; CISPLATIN; CLOSTRIDIUM TOXIN; FURANONE DERIVATIVE; INP 0400; PILICIDE; PILIN; PYRIDONE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG; VIRSTATIN; VIRULENCE FACTOR;

ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACILLUS ANTHRACIS; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CHOLERA; CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI; GENE FUNCTION; MOUSE STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VIBRIO CHOLERAE; YERSINIA;

BACTERIA (MICROORGANISMS);

EID: 34548108138     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2007.24     Document Type: Review

References (62)

1. Palumbi, S.R. Humans as the world's greatest evolutionary force. Science 293, 1786-1790 (2001).
2. Young, J.A. & Collier, R.J. Anthrax toxin: receptor-binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76, 243-265 (2007).
3. Boyden, E.D. & Dietrich, W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38, 240-244 (2006).
4. Duesbery, N.S. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734-737 (1998).
5. Vitale, G. et al. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248, 706-711 (1998).
6. Panchal, R.G. et al. Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis. Chem. Biol. 14, 245-255 (2007).
7. During, R.L. et al. Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation. EMBO J. 26, 2240-2250 (2007).
8. Rainey, G.J. & Young, J.A. Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. 2, 721-726 (2004).
9. Shoop, W.L. et al. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. USA 102, 7958-7963 (2005).
10. Turk, B.E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11, 60-66 (2004).
11. Krantz, B.A. et al. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 309, 777-781 (2005).
12. Artenstein, A.W. et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J. Infect. Dis. 190, 1655-1660 (2004).
13. Sanchez, A.M. et al. Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob. Agents Chemother 51, 2403-2411 (2007).
14. Moayeri, M., Wiggins, J.F., Lindeman, R.E. & Leppla, S.H. Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. 50, 2658-2665 (2006).
15. Ma, T. et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. 110, 1651-1658 (2002).
16. King, C.Y. & Barriere, S.L. Analysis of the in vitro interaction between vancomycin and cholestyramine. Antimicrob. Agents Chemother. 19, 326-327 (1981).
17. Galan, J.E. & Wolf-Watz, H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 444, 567-573 (2006).
18. Kauppi, A.M., Nordfelth, R., Uvell, H., Wolf-Watz, H. & Elofsson, M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10, 241-249 (2003).
19. Nordfelth, R., Kauppi, A.M., Norberg, H.A., Wolf-Watz, H. & Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73, 3104-3114 (2005).
20. Muschiol, S. et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 103, 14566-14571 (2006).
21. Bailey, L. et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581, 587-595 (2007).
22. Hudson, D.L. et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob. Agents Chemother 51, 2631-2635 (2007).
23. Stevens, D.L., Gibbons, A.E., Bergstrom, R. & Winn, V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23-28 (1988).
24. Miller, M.B. & Bassler, B.L. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165-199 (2001).
25. Parsek, M.R., Val, D.L., Hanzelka, B.L., Cronan, J.E. Jr. & Greenberg, E.P. Acyl homoserine-lactone quorum-sensing signal generation. Proc. Natl. Acad. Sci. USA 96, 4360-4365 (1999).
26. Dong, Y.H., Xu, J.L., Li, X.Z. & Zhang, L.H. AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc. Natl. Acad. Sci. USA 97, 3526-3531 (2000).
27. Dong, Y.H. et al. Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 411, 813-817 (2001).
28. Yang, F. et al. Quorum quenching enzyme activity is widely conserved in the sera of mammalian species. FEBS Lett. 579, 3713-3717 (2005).
29. Draganov, D.I. et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46, 1239-1247 (2005).
30. Muh, U. et al. Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob. Agents Chemother. 50, 3674-3679 (2006).
31. Geske, G.D., Wezeman, R.J., Siegel, A.P. & Blackwell, H.E. Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J. Am. Chem. Soc. 127, 12762-12763 (2005).
32. Smith, K.M., Bu, Y. & Suga, H. Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthtic autoinducer analogs. Chem. Biol. 10, 81-89 (2003).
33. Givskov, M. et al. Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. J. Bacteriol. 178, 6618-6622 (1996).
34. Manefield, M. et al. Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. Microbiology 148, 1119-1127 (2002).
35. Manefield, M., Welch, M., Givskov, M., Salmond, G.P. & Kjelleberg, S. Halogenated furanones from the red alga, Delisea pulchra, inhibit carbapenem antibiotic synthesis and exoenzyme virulence factor production in the phytopathogen Erwinia carotovora. FEMS Microbiol. Lett. 205, 131-138 (2001).
36. Hentzer, M. et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148, 87-102 (2002).
37. Hentzer, M. et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22, 3803-3815 (2003).
38. Wu, H. et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53, 1054-1061 (2004).
39. Yates, E.A. et al. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect. Immun. 70, 5635-5646 (2002).
40. Muh, U. et al. A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc. Natl. Acad. Sci. USA 103, 16948-16952 (2006).
41. Lyon, G.J., Wright, J.S., Christopoulos, A., Novick, R.P. & Muir, T.W. Reversible and specific extracellular antagonism of receptor-histidine kinase signaling. J. Biol. Chem. 277, 6247-6253 (2002).
42. Mayville, P. et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl. Acad. Sci. USA 96, 1218-1223 (1999).
43. Wright, J.S. III, Jin, R. & Novick, R.P. Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc. Natl. Acad. Sci. USA 102, 1691-1696 (2005).
44. Hung, D.T., Shakhnovich, E.A., Pierson, E. & Mekalanos, J.J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670-674 (2005).
45. Gauthier, A. et al. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob. Agents Chemother. 49, 4101-4109 (2005).
46. Sauer, F.G. et al. Chaperone-assisted pilus assembly and bacterial attachment. Curr. Opin. Struct. Biol. 10, 548-556 (2000).
47. Svensson, A. et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. ChemBioChem 2, 915-918 (2001).
48. Pinkner, J.S. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Sci. USA 103, 17897-17902 (2006).
49. Lee, Y.M., Almqvist, F. & Hultgren, S.J. Targeting virulence for antimicrobial chemotherapy. Curr. Opin. Pharmacol. 3, 513-519 (2003).
50. Sassetti, C.M. & Rubin, E.J. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. USA 100, 12989-12994 (2003).
51. MacRae, C.A. & Peterson, R.T. Zebrafish-based small molecule discovery. Chem. Biol. 10, 901-908 (2003).
52. Peterson, R.T. et al. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat. Biotechnol. 22, 595-599 (2004).
53. Stern, H.M. et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat. Chem. Biol. 1, 366-370 (2005).
54. Davis, J.M. et al. Real-time visualization of Mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17, 693-702 (2002).
55. Neely, M.N., Pfeifer, J.D. & Caparon, M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect. Immun. 70, 3904-3914 (2002).
56. van der Sar, A.M. et al. Zebrafish embryos as a model host for the real time analysis of Salmonella typhimurium infections. Cell. Microbiol. 5, 601-611 (2003).
57. Mukhopadhyay, A. & Peterson, R.T. Fishing for new antimicrobials. Curr. Opin. Chem. Biol. 10, 327-333 (2006).
58. Moy, T.I. et al. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. USA 103, 10414-10419 (2006).
59. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
60. Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
61. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
62. Sarac, M.S., Peinado, J.R., Leppla, S.H. & Lindberg, I. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect. Immun. 72, 602-605 (2004).